View Schedule

Monday, Nov. 9, 2020

Pre-Conference Program

no_symbol.pngIndicates that the presentation is not available on-demand.

9 a.m.–3:15 p.m. EST*


Immunotherapy Resistance and Failure 

9 a.m. Introduction

Edward Cha, MD, PhD - Genentech

Session I: Defining Immune Checkpoint Inhibitor Resistance

9:05 a.m.

no_symbol.png Definitions of Resistance and Gaps in Current Understanding
Ryan J. Sullivan, MD - Massachusetts General Hospital

9:35 a.m.

Mechanisms of Resistance and Possible New Combinations for Overcoming Them (View On-Demand)
Paolo A. Ascierto, MD - Istituto Nazionale Tumori IRCCS Fondazione Pascale

9:55 a.m.

Immunotherapy Primary and Acquired Resistance (View On-Demand)
Antoni Ribas, MD, PhD - University of California Los Angeles

10:15 a.m.

Break

Session II: Primary Resistance

10:30 a.m.

no_symbol.pngApproaches to Address Primary Resistance
Siwen Hu-Lieskovan, MD, PhD – Huntsman Cancer Institute, University of Utah

10:55 a.m.

Neoadjuvant Immune Checkpoint Blockade: A Window into Treatment Response and Primary Resistance (View On-Demand)
Suzanne L. Topalian, MD - Johns Hopkins University School of Medicine

11:20 a.m.

Coupled scRNA-seq and Intracellular Protein Activity Reveals Immune Suppressive Role of TREM2 in Cancer (View On-Demand)
Yonatan Katzenelenbogen, B.Sc - Weizmann Institute of Science

11:35 a.m.

no_symbol.png¬MHC-I and -II Expression Levels on Tumor cells and T cell Response to Immunotherapy in B78 Murine Melanoma Model
Amy K. Erbe, PhD - University of Wisconsin

11:50 a.m.

Break

Session III: Secondary/Acquired Resistance
12:20 p.m.

no_symbol.pngApproaches to Address Acquired Resistance
Kevin J. Harrington, PhD, MD - The Institute of Cancer Research

12:45 p.m.

no_symbol.pngOvercoming Acquired Resistance in anti-PD-1 Therapy by Simultaneously Depleting Tumor and All Major Types of Immunosuppressive cells
Yong Lu, PhD - Wake Forest School of Medicine

1:00 p.m.

no_symbol.pngPreclinical Antitumor Activity of OncoVEXmGM-CSF in Combination with PD-1/PD-L1 Inhibitors in PD-L1 Resistant Mouse Models Supports the MASTERKEY-115 Study
Jing Qing, PhD - Amgen Inc.

1:15 p.m.

Break

Session IV: Therapeutic Strategies for Patients with Resistant Disease
1:30 p.m.

no_symbol.pngAssessment of Circulating Tumor DNA (ctDNA) and Plasma Microsatellite Instability (MSI) during PD-1 Blockade
Pashtoon M. Kasi, MD, MS - University of Iowa

1:45 p.m.

Radiological Dynamics and Resistance Types in Patients with Advanced Melanoma Treated with anti-PD-1 Monotherapy (View On-Demand)
Xue Bai, MD - Peking University Cancer Hospital & MGH

2:00 p.m.

no_symbol.pngPrecision Microbiome Mapping Identifies a Microbiome Signature Predictive of Immune Checkpoint Inhibitor Response Across Multiple Research Study Cohorts
Matthew J. Robinson, PhD - Microbiotica

2:15 p.m.

no_symbol.pngRegulatory Considerations
Marc Theoret, MD - U.S. Food and Drug Administration, OHOP

2:40 p.m.

no_symbol.pngPanel Discussion

3:10 p.m.

Closing Remarks
Israel Lowy, MD, PhD - Regeneron Pharmaceuticals

Tuesday, Nov. 10, 2020 

Pre-Conference Program

no_symbol.pngIndicates that the presentation is not available on-demand.

Sponsored Symposia: Medscape: A Deep Dive Into Immunotherapy in Advanced Endometrial Cancer

7:30–8:30 a.m. EST

8 a.m.–9 a.m. EST

World Immunotherapy Council's Virtual Young Investigator Session


8 a.m.

 

Introduction
Bernard A. Fox, PhD - Providence Cancer Institute

8:05 a.m.

A combination of functional biomarkers improves identification of the tumor-specific reactive T cell repertoire (View On-Demand)
Arianna Draghi – National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital

8:15 a.m.

no_symbol.pngDeep immune profiling of SARS-CoV-2 associated immune microenvironment in cancer tissues from recovered COVID-19 patients
Denise Goh, BBiomedSc (Hons) – Institute of Molecular and Cell Biology (IMCB), Agency of Science, Technology and Research (A*STAR), Singapore

8:25 a.m.

Expert Discussant
Tanja D. de Gruijl, PhD – VU University Amsterdam

8:30 a.m.

no_symbol.pngAnti-LunX targeting therapy for lung cancer
Xiaohu Zheng – University of Science and Technology of China

8:40 a.m.

no_symbol.pngIdentification of tumor antigen-specific T cells in the peripheral blood of colorectal cancer patients
Emilie Picard, PhD – Health Sciences North/Horizon Sante Nord

8:50 a.m.

Expert Discussant 
Bernard A. Fox, PhD – Providence Cancer Institute

8:55 a.m.

Closing  
Bernard A. Fox, PhD – Providence Cancer Institute

9 a.m.–11:45 a.m. EST

Grant Writing Workshop


9 a.m.

 

Welcome Remarks
Claire Vanpouille-Box, PhD – Weill Medical College of Cornell University

9:05 a.m.

Overview of Grant Opportunities and Principles of Grant Writing (View On-Demand)
Pawel Kalinski, MD, PhD – Roswell Park Comprehensive Cancer Institute

9:30 a.m.

K Awards and R01 Grants (View On-Demand)
William Matsui, MD – University of Texas at Austin

9:55 a.m.

How to Write a Specific Aims Page  (View On-Demand)
Thomas Gajewski, MD, PhD – University of Chicago

10:30 a.m.

Panel Discussion 
Moderator:
David Aggen, MD, PhD – Memorial Sloan Kettering Cancer Center

Panelists:

William Matsui, MD – University of Texas at Austin
Thomas Gajewski, MD, PhD – University of Chicago
Pawel Kalinski, MD, PhD – Roswell Park Comprehensive Cancer Institute
Malgorzata Klauzinska, PhD – National Institutes of Health

10:45 a.m.

Mock Study Section
Moderator:
Zhang-Zhi Hu, MD- National Institute of Health

Panelists:
Scientific Review Officer - Malgorzata Klauzinska, PhD – National Institutes of Health
Chair - Thomas Gajewski, PhD – University of Chicago
Primary Reviewer - Pawel Kalinski, MD, PhD – Roswell Park Comprehensive Cancer Institute
Secondary Reviewer - William Matsui, MD – University of Texas at Austin
Third Reviewer – Robyn Gartrell, MD – Columbia University/New York Presbyterian
Reader - Olivia Rongze Lu, PhD – University of Texas at Austin, Dell Medical School

11:10 a.m.

What Happens After the Study Section? (View On-Demand)
Malgorzata Klauzinska, PhD – National Institutes of Health

11:30 a.m.

Panel Discussion 
Moderator:
Grey Wilkinson, PhD – Oncolytics Biotech Inc.

Panelists:
William Matsui, MD – University of Texas at Austin
Thomas Gajewski, PhD – University of Chicago
Pawel Kalinski, PhD – Roswell Park Comprehensive Cancer Institute
Malgorzata Klauzinska, PhD – National Institutes of Health
Zhang-Zhi Hu, MD- National Institute of Health

11:40 a.m.

Closing Remarks
Olivia Rongze Lu, PhD – University of Texas at Austin, Dell Medical School

9 a.m.–2:55 p.m. EST 

Workshop on Engineering Immune Cells for Cancer Therapy 

Session I: Advances in Adoptive T cell Therapy for Cancer: TILs and TCRs

9 a.m. Introduction

Katy Rezvani, MD, PhD – The University of Texas MD Anderson Cancer Center

9:05 a.m.

Cellular Immunotherapy for Metastatic Cancers (View On-Demand)
Steven A. Rosenberg, MD, PhD – National Cancer Institute, National Institutes of Health

9:25 a.m.

Adoptive Therapy Utilizing TILs (View On-Demand)
John Haanen, MD, PhD – Netherlands Cancer Institute

9:45 a.m.

Endogenous T cell Therapy for Solid Tumors Malignancies (View On-Demand)
Cassian Yee, MD – The University of Texas MD Anderson Cancer Center

10:05 a.m.

Session I Panel Discussion - Session I Speakers

10:20 a.m.

Break

Session II: Novel Approaches to Enhance CAR T cell Therapy

10:35 a.m.

no_symbol.png Next-generation CARs for Blood Cancers
Michael Hudecek, MD –University of Wuerzburg

10:55 a.m.

no_symbol.pngAdvancing Immunotherapy Platforms for the Treatment of Solid Tumors
Saul Priceman, PhD – City of Hope

11:15 a.m.

no_symbol.pngUnderstanding Resistance to CAR T-cell Therapy to Develop Next-generation Immunotherapies
Marco Ruella, MD – University of Pennsylvania

11:35 a.m.

Session II Panel Discussion - Session II Speakers

11:50 a.m.

Break

Session III: CAR-Based Strategies Beyond T Lymphocytes
12:05 p.m.

no_symbol.pngCAR NK cells for the Immunotherapy of Cancer 
Katy Rezvani, MD, PhD – The University of Texas MD Anderson Cancer Center

12:25 p.m.

no_symbol.pngThe Development of CAR Macrophages and Monocytes for Cancer Immunotherapy
Michael Klichinsky, PharmD, PhD – Carisma Therapeutics

12:45 p.m.

no_symbol.pngEngineering B cells to Produce Therapeutic Antibodies
Justin J. Taylor, PhD – Fred Hutchinson Cancer Research Center

1:05 p.m.

Session III Panel Discussion - Session III Speakers

1:20 p.m.

Break

Session IV: Integration of Novel Technologies for CAR Therapy and their Translation to the Clinic
1:35 p.m.

no_symbol.pngThe Evolving Process of Clinical CAR T Cell Manufacturing in the Academic Setting
Isabelle C. Rivière, PhD – Memorial Sloan Kettering Cancer Center

1:55 p.m.

no_symbol.pngAllogeneic CAR T therapy for Cancer
Barbra J. Sasu, PhD – Allogene Therapeutics

2:15 p.m.

Corona Madness: Flattening the Curve with CAR T (View On-Demand)
Carl H. June, MD – University of Pennsylvania

2:35 p.m.

Session IV Panel Discussion - Session IV Speakers

2:50 p.m.

Closing Remarks
Christine Brown, PhD – City of Hope

9 a.m.–3:55 p.m. EST

Primer on Tumor Immunology and Cancer Immunotherapy

(CE Credit Available)


Session I: Generating Anti-Tumor Immunity

9 a.m.

 

Introduction
Michael A. Curran, PhD – The University of Texas MD Anderson Cancer Center

9:05 a.m.

no_symbol.pngThe Adaptive Immune Response
Jonathan Powell, MD, PhD – Johns Hopkins University School of Medicine

9:35 a.m.

no_symbol.pngDendritic Cells and Myeloid cues in the Tumor Microenvironment
Niroshana Anandasabapathy, MD, PhD - Weill Cornell Medicine

10 a.m.

Myeloid-derived Suppressor Cells as Negative Regulators of Immune Responses in Cancer (View On-Demand)
Dmitry I. Gabrilovich, MD, PhDAstraZeneca

10:25 a.m.

Session I Panel Discussion - Session I Speakers

10:40 a.m.

Break

Session II: Approaches to Immunotherapy I

10:55 a.m.

Introduction
Michael A. Curran, PhD – The University of Texas MD Anderson Cancer Center

11 a.m.

T cell Checkpoint Blockade/Costimulation (View On-Demand)
James P. Allison, PhD – The University of Texas MD Anderson Cancer Center

11:25 a.m.

no_symbol.pngCancer Vaccines 
Ugur Sahin, MD – BioNTech Group 
(*No Credit) 

11:50 a.m.

The Suppressive Yin Versus Pro-Inflammatory Yang of the Tumor Myeloid Stroma (View On-Demand)
Michael A. Curran, PhD – The University of Texas MD Anderson Cancer Center

12:15 p.m.

Session II Panel Discussion - Session II Speakers

12:30 p.m.

Break

Session III: Approaches to Immunotherapy II
12:50 p.m.

Introduction
Yvonne Saenger, MD – Columbia University/New York Presbyterian

12:55 p.m.

no_symbol.pngBe all that you can B: Imprinting an Antitumor T cell Army
Chrystal M. Paulos, PhD – Winship Cancer Institute at Emory University 

1:20 p.m.

Immunometabolism and its Potential to Modify the Tumor Microenvironment (View On-Demand)
Greg M. Delgoffe, PhD – University of Pittsburgh

1:45 p.m.

Mobilizing the Immune System with Bispecific Antibodies (View On-Demand)
John R. Desjarlais, PhD – Xencor, Inc.

2:10 p.m.

Session III Panel Discussion - Session III Speakers

2:25 p.m.

Break

Session IV: Clinical Practice of Immunotherapy 
2:40 p.m.

Introduction
Michael A. Curran, PhD – The University of Texas MD Anderson Cancer Center

2:45 p.m.

Immune Biomarkers to Guide Clinical Care (View On-Demand)
Yvonne Saenger, MD – Columbia University/New York Presbyterian

3:10 p.m.

Immune Related Adverse Events (View On-Demand)
Michael Postow, MD – Memorial Sloan Kettering Cancer Center 

3:35 p.m.

Session IV Panel Discussion - Session IV Speakers

3:50 p.m.

Closing Remarks
Yvonne Saenger, MD – Columbia University/New York Presbyterian

Wednesday, Nov. 11, 2020

Annual Meeting

8:30 a.m. – 8 p.m. EST*

no_symbol.pngIndicates that the presentation is not available on-demand.

Sponsored Symposia: NanoString Technologies: New Approaches for CAR-T Therapies: Technology Symposium featuring GeoMx spatial profiling and Counter CAR-T Characterization 

7:30–8:30 a.m. EST

Sponsored Symposia: Natera: Clinical Applications of ctDNA Testing for Immunotherapy Response Monitoring

8–8:30 a.m. EST

Anniversary Awards Ceremony 
Chair:
Mario Sznol, MD – Yale School of Medicine
8:30–9 a.m. EST

8:30 a.m.

Introduction 
Mario Sznol, MD – Yale School of Medicine

 

Public Service Award

 

Patient Advocacy Award

Session 100: Presidential Welcome & Rosenberg Award Announcement
Chair:
Mario Sznol, MD – Yale School of Medicine

9–9:30 a.m. EST

Mario Sznol, MD – Yale School of Medicine

Session 101: Richard V. Smalley, MD Memorial Award and Lectureship: Discovery, Development, and Application of the PD-1/PD-L1; B7-H1 Antagonist Antibodies
Chair:
Mario Sznol, MD – Yale School of Medicine
9:30–11 a.m. EST
(CE Credit Available)

9:30 a.m.

The PD-L1/PD-1 Pathway: Discovery and New Insights (View On-Demand)
Gordon Freeman, PhD – Dana-Farber Cancer Institute

10 a.m.

no_symbol.pngWhy Were We Interested in Immunity Within the Tumor Microenvironment in the 1990s?
Lieping Chen, MD, PhD – Yale School of Medicine

10:30 a.m.

no_symbol.pngDiscovery of New IO Targets and Mechanisms Leveraging CRISPR 
Arlene Sharpe, MD, PhD – Harvard Medical School
(*No Credit)

11–11:15 a.m. EST

Break

Session 102: Combinatorial Therapies
Co-Chairs:
Charlotte E. Ariyan, MD, PhD – Memorial Sloan Kettering Cancer Center
Silvia Formenti, MD Weill Cornell Medicine
11:15 a.m.–1:10 p.m. EST
(CE Credit Available)

Organized in collaboration with the Radiosurgery Society (RSS)

11:15 a.m.

Introduction

11:20 a.m.

no_symbol.png(470) Targeting Pan-Tumor Associated Antigen B7H3 via Combination of Tri-specific Killer Engager and Off-the-shelf NK Cell Therapy Enhances Specificity and Function Against a Broad Range of Solid Tumors
Nicholas Zorko, MD, PhD – University of Minnesota

11:30 a.m.

no_symbol.png(446) Immunopeptidome changes mediated by a novel ERAP1 inhibitor leads to tumor growth inhibition
Peter Joyce, PhD - Grey Wolf Therapeutics Limited

11:40 a.m.

(362) A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis (View On-Demand)
James Spicer, PhD, FRCP - King's College London

11:50 a.m.

Expert Discussant

12:05 p.m.

Q&A

12:15 p.m.

(200) NBTXR3 nanoparticle with immunoradiation improves survival and generates long-term anti-tumor memory in an anti-PD1 resistant Murine Lung Cancer Model (View On-Demand)
Yun Hu, PhD - The University of Texas MD Anderson Cancer Center

12:25 p.m.

no_symbol.png(368) REVEAL: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for treating solid tumors
Adi Diab, MD - The University of Texas MD Anderson Cancer Center

12:35 p.m. (386) Phase I/Ib first-in-human study of HEK-NIZ985, a recombinant IL-15/IL-15Rα heterodimer, alone and in combination with spartalizumab, in adults with advanced and metastatic solid tumors (View On-Demand)
John Thompson, MD - University of Washington Seattle Cancer Care
12:45 p.m.

Expert Discussant
Chandan Guha, MB, BS, PhD – Montefiore Medical Center

1 p.m.

Q&A

 

1:10–1:30 p.m. EST

Break

1–2 p.m. EST

Virtual Exhibit and Poster Hall Hours

Concurrent Session 103: Rapid Oral Abstract Presentation: Basic Research
Co-Chairs:
Sarah Church, PhD – NanoString Technologies
Brendan Horton, PhD – Massachusetts institute of Technology
1:30–2 p.m. EST

1:30 p.m.

(90) Potentiation of T-cell mediated tumor killing via modulation of the fas/fasL pathway (View On-Demand)
Jonathan Boiarsky, BA - Icahn School of Medicine at Mount Sinai

1:38 p.m.

(209) Preclinical mechanistic and clinical evaluation of the corticosteroid dexamethasone’s detrimental effects on immune checkpoint blockade in glioblastoma cancer (View On-Demand)
Bryan Iorgulescu, MD - Dana-Farber Cancer Institute

1:46 p.m.

(472) ImmunoPET-informed sequence for focused ultrasound-targeted mCD47 blockade controls glioma (View On-Demand)
Natasha D. Sheybani, PhD - University of Virginia

1:54 p.m.

Q&A

Concurrent Session 104: Rapid Oral Abstract Presentation: Clinical
Co-Chairs:
Ravi Patel, MD, PhD – University of Pittsburgh
Jessica Thaxton, PhD, MSCR – Medical University of South Carolina
1:30–2 p.m. EST
(CE Credit Available)

1:30 p.m.

no_symbol.png(420) Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study
Adi Diab, MD - The University of Texas MD Anderson Cancer Center

1:38 p.m.

no_symbol.png(547) Identification of the immune landscape in penile squamous cell carcinoma using multiplex immunofluorescence and spatial image analysis
Rossana N. Lazcano Segura, MD - The University of Texas MD Anderson Cancer Center

1:46 p.m.

(455) Impact of EphB4 and PD-1 treatment on immune infiltrate in advanced bladder cancer (View On-Demand)
Sarmad Sadeghi, MD - Keck School of Medicine of USC

1:54 p.m.

Q&A

Session 105: Integrating Radiation and Immunotherapy: New Products, Challenges, and Opportunities for Industry-Academic Collaborations
Co-Chairs:
Zachary Morris, MD, PhD – University of Wisconsin, Madison
Andrew Sikora, MD, PhD – University of Texas MD Anderson Cancer Center
2–3:30 p.m. EST
(CE Credit Available)

2 p.m.

Introduction
Andrew Sikora, MD, PhD University of Texas MD Anderson Cancer Center

2:05 p.m.

The Immuno-Radiobiology of Radiation Therapy (View On-Demand)
Zachary Morris, MD, PhD – University of Wisconsin, Madison

2:20 p.m.

no_symbol.pngOptimal Sequencing of Radiation and Immunotherapy
Silvia Formenti, MD – Weill Cornell Medicine

2:35 p.m.

Design of Clinical Trials Integrating Radiation and Immunotherapy (View On-Demand)
Jonathan D. Schoenfeld, MD, MPhil, MPH Harvard University

2:50 p.m.

no_symbol.pngNCI SBIR Opportunities
Kory Hallet, PhD – NCI SBIR Development Center

3 p.m.

Best Practices and Future Perspectives for Integrating Radiation and Immunotherapy Panel Discussion
(*No Credit)
Mansoor Ahmed, PhD – National Cancer Institute
Michael Basseti, MD, PhD – University of Wisconsin, Madison
Sue L. Currie, PhD Nektar Therapeutics

Sandra Demaria, MD Weill Cornell Medicine
Silvia Formenti, MD – Weill Cornell Medicine
Kory Hallet, PhD – NCI SBIR Development Center
Tibor Keler, PhD – Celldex Therapeutics, Inc.
Samir Khleif, MD – Georgetown University Medical Center
Sophia Pfister, PhD – Varian

Jonathan D. Schoenfeld, MD, MPhil, MPH Harvard University
Andrew Sharabi, MD, PhD – Moores Cancer Center
Chiayeng Wang, PhD – National Cancer Institute, NIH
Kristina H. Young, MD, PhD Earle A. Chiles Research Institute

3:25 p.m.

Closing Remarks

3:30–4:45 p.m. EST

Break

Concurrent Session 106: Developing Cellular Therapies for Solid Cancers
Co-Chairs:
Stephanie L. Goff, MD, FACS – National Cancer Institute
Avery Posey, PhD – University of Pennsylvania School of Medicine
3:45–5:15 p.m. EST
(CE Credit Available)

3:45 p.m.

TILS (View On-Demand)
Michal Besser, PhD – The Sheba Medical Center at Tel Hashomer

4:05 p.m.

no_symbol.pngTCR Cells
James C. Yang, MD – National Cancer Institute

4:25 p.m.

no_symbol.pngCAR for Solid Tumors
Avery Posey, PhD – University of Pennsylvania School of Medicine

4:45 p.m.

no_symbol.pngNKT Cells
Andras A. Heczey, MD – Baylor College of Medicine

5:05 p.m.

(122) Guanylyl cyclase C as a target for CAR-T cell therapy in a metastatic gastric cancer model (View On-Demand)
Amanda N. Lisby, MS - Thomas Jefferson University

Concurrent Session 107: Neoadjuvant Immunotherapies
Co-Chairs:
Padmanee Sharma, MD, PhD – The University of Texas MD Anderson Cancer Center
Janis M. Taube, MD, MSc – Johns Hopkins School of Medicine

3:45–5:15 p.m. EST
(CE Credit Available)

3:45 p.m.

no_symbol.pngPan-Tumor Pathologic Response Assessment
Janis M. Taube, MD, MSc – Johns Hopkins School of Medicine

4:05 p.m.

Neoadjuvant Breast Cancer (View On-Demand)
Elizabeth A. Mittendorf, MD, PhD – Dana-Farber Cancer Institute Brigham & Woman's Cancer Institute

4:25 p.m.

Bladder Cancer (Treme/Durva) (View On-Demand)
Jianjun Gao, MD, PhD – The University of Texas MD Anderson Cancer Center

4:45 p.m.

no_symbol.png(432) 3-year results of the phase 2 randomized trial for talimogene laherparepvec (T-VEC) neoadjuvant treatment plus surgery vs surgery in patients with resectable stage IIIB-IVM1a melanoma
Reinhard Dummer, MD - University Hospital of Zurich

5 p.m.

no_symbol.png(264) Correlation of virus-specific CD8+ T cells to clinical response following treatment with Pexa-Vec and Cemiplimab in patients with advanced renal cell carcinoma
Raquel Deering, PhD – Regeneron Pharmaceuticals, Inc.

Concurrent Session 108: Diet and Microbiome
Co-Chairs:
Jeremiah Faith, PhD – Icahn Institute for Data Science and Genomic Technology at Mt. Sinai
Laurence Zitvogel, MD, PhD – Institut Gustave Roussy

3:45–5:15 p.m. EST
(CE Credit Available)

3:45 p.m.

Introduction into Microbiome & Diet
Jeremiah Faith, PhD – Icahn Institute for Data Science and Genomic Technology at Mt. Sinai

4 p.m.

no_symbol.pngMicronutrients with Immunostimulatory Properties
Guido Kroemer, MD, PhD – Institut Gustave Roussy

4:20 p.m.

no_symbol.pngLinking the gut microbiome to cancer immunotherapy response
Meriem Messaoudene, PhD – CRCHUM, Bertrand Routy Lab

4:40 p.m.

no_symbol.pngDiet, the microbiome, and immune response: From observation to intervention
Jennifer L. McQuade, MD – The University of Texas MD Anderson Cancer Center

5 p.m.

no_symbol.png(672) Identification of microbial-derived HLA-bound peptides in melanoma
Adi Nagler, MSc - Weizmann

Concurrent Session 109: Innate Immunity: The Next Generation of Targets for Anti-Cancer Immunotherapy
Co-Chairs:
Jennifer L. Guerriero, PhD – Dana-Farber Cancer Institute
Katayoun Rezvani, MD, PhD – The University of Texas MD Anderson Cancer Center

3:45–5:15 p.m. EST
(CE Credit Available)

3:45 p.m.

Harnessing Tumor Associated Macrophages for Anti-Cancer Therapy (View On-Demand)
Jennifer L. Guerriero, PhD – Dana-Farber Cancer Institute

4:05 p.m.

no_symbol.pngGamma-delta T cells
Adrian Hayday, FRS, F MedSci – Gamma Delta Therapeutics

4:25 p.m.

no_symbol.pngNK Cells
Andreas Lundqvist, PhD – Karolinska Institutet

4:45 p.m.

no_symbol.png(531) AFM13-targeted blood and cord-blood-derived memory-like NK cells as therapy for CD30+ malignancies
Nancy D. Marin, PhD - Washington University, St. Louis

5 p.m.

no_symbol.png(539) High dimensional analysis of the human lymph node during melanoma progression reveals shifts in myeloid content that relate to differential T cell content
Anastasia Prokopi, PhD - Amsterdam, UMC

5–6 p.m. EST

Virtual Exhibit and Poster Hall Hours

Session 110: E-Poster Viewing Session

5:15–5:45 p.m. EST

Session 111: The Surgeon's Impact on Tumor Immunotherapy: Recent Achievements and Future Promise
Co-Chairs:
Brian R. Gastman, MD – Cleveland Clinic Cancer Center

Howard L. Kaufman, MD, FACS – Immuneering Corporation
5:30–6:30 p.m. EST

5:30 p.m

Introduction
Brian R. Gastman, MD – Cleveland Clinic Cancer Center

5:35 p.m.

Oncolytic Viruses: The Importance of Surgical Input (View On-Demand)
Howard L. Kaufman, MD, FACS – Immuneering Corporation

5:45 p.m. (274) Tumoral and peripheral immunophenotype of refractory vs relapse to PD-(L)1 blockade in patients with advanced Non-Small Cell Lung Cancer (View On-Demand)
Maria L. Ascierto, PhD – AstraZeneca

5:50 p.m. (277) Combined neoadjuvant chemo-immunotherapy therapy achieves superior downstaging of resectable non-small cell lung cancer as compared to chemotherapy, mono or dual immunotherapy (View On-Demand)
Boris Sepesi, MD - The University of Texas MD Anderson Cancer Center

5:55 p.m. (303) Phase II Trial of Neoadjuvant Nivolumab (Nivo) and Intra-Tumoral (IT) CMP-001 in High-Risk Resectable (View On-Demand)
Diwakar Davar, MD – UPMC Hillman Cancer Center

6:00 p.m. no_symbol.png(449) Neoadjuvant cyclic dinucleotides combined with interleukin-2 and anti-PD-1 antibody limit lung metastasis of orthotopic breast tumors through prolonged NK cell activation
Lauren Milling, BS - Massachusetts Institute of Technology

6:05 p.m. no_symbol.png(254) CTLA-4 blockade promotes Treg glucose metabolism and reduces Treg functional stability in glycolysis-defective tumors
Roberta Zappasodi, PhD - Memorial Sloan Kettering Cancer Center

6:10 p.m. Expert Discussant
Steven A. Rosenberg, MD, PhD – National Cancer Institute

6:20 p.m. Q&A

6:30–7 p.m. EST

Break

Replay Session with Live Q&A: Session 103: Rapid Oral Abstracts: Basic Research

7–8 p.m. EST

Co-Chairs:
Sarah Church, PhD – NanoString Technologies
Brendan Horton, PhD – Massachusetts Institute of Technology

Replay Session with Live Q&A: Session 104: Rapid Oral Abstracts: Clinical

7–8 p.m. EST

Co-Chairs:
Ravi Patel, MD, PhD – University of Pittsburgh
Jessica Thaxton, PhD, MSCR – Medical University of South Carolina

On-Demand Sessions

Update Session: National Cancer Institute (NCI) (View On-Demand)
Norman E. Sharpless, MD - National Cancer Institute

Update Session: Food and Drug Administration (FDA) no_symbol.png
Raj Puri, MD, PhD – U.S. Food and Drug Administration

no_symbol.pngUpdate Session: FDA Oncology Center of Excellence (FDA OCE)
Marc Theoret, MD – U.S. Food and Drug Administration

Update Session: Cancer Immunotherapy Trials Network (CITN) (View On-Demand)
Martin A. Cheever, MD - Fred Hutchinson Cancer Research Center

no_symbol.pngUpdate Session: SITC Policy Committee
G
eorge J. Weiner, MD - University of Iowa, Holden Comprehensive Cancer Center

Update Session: SITC Women in Cancer Immunotherapy Network (WIN) (View On-Demand)
Lisa H. Butterfield, PhD – Parker Institute for Cancer Immunotherapy

no_symbol.pngUpdate Session: International Neoadjuvant Melanoma Consortium (INMC)
Elizabeth M. Burton, MBA – MD Anderson Cancer Center

Thursday, Nov. 12, 2020

Annual Meeting

8:30 a.m. – 8 p.m. EST*

no_symbol.pngIndicates that the presentation is not available on-demand.

Sponsored Symposia: OncoSec-DNA Plasmid-based IL-2 Delivered Intratumoral Electroporation: Achieving Meaningful Tumor Responses While Avoiding Systemic Toxicities 

7:30–8:30 a.m. EST

Anniversary Awards Ceremony
Chair: Mario Sznol, MD – Yale School of Medicine
8:30–9 a.m. EST

8:30 a.m.

Introduction
Mario Sznol, MD – Yale School of Medicine

8:32 a.m.

Extraordinary Service Awards

8:44 a.m.

Visionary/Leagacy Award

Session 200: Keynote Address
Chair:
Mario Sznol, MD – Yale School of Medicine
9–9:50 a.m. EST
(CE Credit Available)

9 a.m.

Introduction
Mario Sznol, MD – Yale School of Medicine

9:05 a.m.

Turning Immunologically Quiescent Tumors into Immune Responsive Cancers (View On-Demand)
Elizabeth M. Jaffee, MD – Sidney Kimmel Cancer Center, Johns Hopkins University

9:45 a.m.

Q&A
Elizabeth M. Jaffee, MD – Sidney Kimmel Cancer Center, Johns Hopkins University

9:50–10:05 a.m. EST

Break

Session 201: Exploring the Tumor Microenvironment
Co-Chairs:
Vincenzo Bronte, MD – University of Verona
Miriam Merad, MD, PhD– Icahn School of Medicine at Mount Sinai
10:05 a.m.–noon EST
(CE Credit Available)

10:05 a.m.

Introduction

10:15 a.m.

no_symbol.pngStromal Cells in Health, Disease and Immunotherapy
Shannon J. Turley, PhD – Genentech

10:40 a.m.

Exploring and Exploiting the Immune Landscape in Brain Cancers (View On-Demand)
Johanna A. Joyce, PhD – University of Lausanne & Ludwig Institute for Cancer Research

11:05 a.m.

Investigating Genetic Control of the Tumor Microenvironment by Spatial Functional Genomics (View On-Demand)
Brian D. Brown, PhD – Icahn School of Medicine at Mount Sinai

11:30 a.m.

no_symbol.png(670) TJ210 (MOR210), A Differentiated Anti-C5aR Antibody for Anti-Cancer Therapy
Jane Meng, PhD - I-Mab Biopharma

11:45 a.m.

(591) Comparison of Two oHSV Vectors for the Treatment of Glioblastoma (View On-Demand)
Joseph Jackson, PhD - University of Pittsburgh

Session 202: Late-Breaking Abstract Session
Noon–12:30 p.m. EST
Chair:
Sandra Demaria, MD – Weill Cornell Medicine
(CE Credit Available)

Noon (CE Credit Available)

(773) Phenotypic Correlates of Adoptive Cell Therapy Response in Melanoma (View On-Demand)
Sri Krishna, PhD – National Cancer Institute

12:15 p.m.

no_symbol.png(788) Pembrolizumab for Patients with Leptomeningeal Metastasis from Solid Tumors: Efficacy, Safety and Cerebrospinal Fluid Biomarkers
Jarushka Naidoo, MBBCH, MHS – Johns Hopkins Sidney Kimmel Cancer Center

Sponsored Symposia: Personalis: Maximizing Immunotherapy Biomarker Discovery with a Multi-Dimensional Tumor Immunogenomics Platform

12:30–12:50 p.m. EST

12:30–12:50 p.m. EST

Break

12:30–1:30 p.m. EST

Virtual Exhibit and Poster Hall Hours

Concurrent Session 203: Rapid Oral Abstract Presentation: Basic Research
Co-Chairs:
Kristin Anderson, PhD – Fred Huchinson Cancer Research Center
Spencer Wei, PhD – Spotlight Therapeutics
12:50–1:20 p.m. EST

12:50 p.m.

no_symbol.png(512) Terminally exhausted CD8+ T cells potentiate the tolerogenic tumor microenvironment as functional
suppressors
Paolo D.A. Vignali, BS — The University of Pittsburgh School of Medicine

12:58 p.m.

(755) CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity (View On-Demand)
Alvaro Teijeira - CIMA Pamplona

1:06 p.m.

no_symbol.png(517) Regulatory T cell functional identity is sustained by a glucose: lactate axis that is exploited in the tumor microenvironment
McLane Watson, BS - University Of Pittsburgh

1:14 p.m.

Q&A

Concurrent Session 204: Rapid Oral Abstract Presentation: Clinical
Co-Chairs:
Robyn Gartrell, MD, MS – Columbia University
Saman Maleki, PhD – Western University
12:50–1:20 p.m. EST
(CE Credit Available)

12:50 p.m.

(294) CD8 PET imaging of tumor infiltrating T cells in advanced solid tumors: a phase I first-in-human study of 89Zr-IAB22M2C, a radiolabeled anti-CD8 minibody (View On-Demand)
Michael D. Farwell, MD - University of Pennsylvania

12:58 p.m.

(588) Targeting GITR enhances human tumour-infiltrating T cell functionality in mismatch repair proficient primary colorectal carcinoma and liver metastases (View On-Demand)
Yannick S. Rakké, MD, MSc - Erasmus University Medical Center

1:06 p.m.

(31) Dynamic change of PD-L1 expression on extracellular vesicles predicts response to immune-checkpoint inhibitors in non-small cell lung cancer patients (View On-Demand)
Diego de Miguel Perez, PhD, MSc - University of Maryland

1:14 p.m.

Q&A

Session 205: Toxicities of Cancer Immunotherapy 
Co-Chairs:
Caroline Robert, MD, PhD – Institut Gustave Roussy
Cameron J. Turtle, MBBS, PhD, FRACP – Fred Hutchinson Cancer Research Center

1:20–3:05 p.m. EST
(CE Credit Available)

1:20 p.m.

Toxicities from ICIs (View On-Demand)
Caroline Robert, MD, PhD – Institut Gustave Roussy

1:45 p.m.

no_symbol.pngFactors Associated with Toxicities of CD19 CAR-T cell Immunotherapy
Cameron J. Turtle, MBBS, PhD, FRACP – Fred Hutchinson Cancer Research Center

2:10 p.m.

no_symbol.pngCAR-T Studies
Ansuman T. Satpathy, MD, PhD – Stanford

2:35 p.m.

(653) Dasatinib as a rapid pharmacological ON/OFF switch for T cell bispecific antibody-induced T cell activation and cytokine release (View On-Demand)
Gabrielle Leclercq, MSc - Roche

2:50 p.m.

(645) Preclinical development of a novel colon-targeted therapeutic for the treatment of Immune Checkpoint Inhibitor (ICI)-colitis (View On-Demand)
Nazli Dizman, MD - Yale New Haven Hospital

3:05–3:20 p.m. EST

Break

Concurrent Session 206: Vaccines and Immunoprevention
Co-Chairs:
Shizuko Sei, MD – National Cancer Institute
Catherine J. Wu, MD– Dana-Farber Cancer Institute
3:20–4:50 p.m. EST
(CE Credit Available)

3:20 p.m.

no_symbol.pngPersonal Cancer Vaccines: on the Path to Effective Cancer Immunity
Catherine J. Wu, MD – Dana-Farber Cancer Institute

3:50 p.m.

no_symbol.pngCancer Vaccines for Lynch Syndrome Carrier
Eduardo Vilar-Sanchez, MD, PhD  The University of Texas MD Anderson Cancer Center

4:20 p.m.

(598) Reversal of epigenetic silencing of cGAS and STING in melanoma enhances the activity of tumor infiltrating lymphocytes (View On-Demand)
Rana Falahat, PhD - Moffit Cancer Center

4:35 p.m.

(612) Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141+ dendritic cells to activate naïve and memory NY-ESO-1-specific CD8+ T cells (View On-Demand)
Kristen Radford, PhD - Mater Research Institute

Concurrent Session 207: Gene Editing
Co-Chairs:
Helen E. Heslop, MD – Baylor College of Medicine
Carl H. June, MD– University of Pennsylvania
3:20–4:50 p.m. EST

3:20 p.m.

Panelists
Matthew Porteus, MD, PhD – Stanford University
Vijay Peddareddigari, MD – Tmunity
Zhaohui Ye, PhD, PI Regulatory – FDA, Center for Biologics Evaluation and Research
Chrystal Louis, MD, MPH – CRISPR Therapeutics

Concurrent Session 208: Bispecific Antibodies in Cancer Immunotherapy
Co-Chairs:
Dimitris Skokos, PhD – Regeneron Pharmaceuticals, Inc.
Mario Sznol, MD– Yale School of Medicine
3:20–4:50 p.m. EST

3:20 p.m.

no_symbol.pngHuman Costimulatory Bispecific Antibodies in Cancer Immunotherapy
Dimitris Skokos, PhD – Regeneron Pharmaceuticals, Inc.

3:40 p.m.

no_symbol.pngPD1-IL2v: A Next Generation, PD-1-targeted IL-2R Agonist for Cancer Immunotherapy
Pablo Umana – Roche Innovation Center Zurich

4 p.m.

no_symbol.png(633) Dual-targeting of 4-1BB and OX40 with an ADAPTIR™ bispecific antibody enhances anti-tumor responses to solid tumor
Michelle H. Nelson, PhD - Aptevo Therapeutics

4:15 p.m.

(632) HPN601 is a protease-activated EpCAM-targeting T cell engager with an improved safety profile for the treatment of solid tumors (View On-Demand)
Jack Lin, PhD - Harpoon Therapeutics

4:30 p.m.

(359) AMG 757, a half-life extended bispecific T-cell engager (BiTE®) immune therapy against DLL3 in SCLC: phase 1 interim results (View On-Demand)
Hossein Borghaei, MS, DO - Fox Chase Cancer Center

Concurrent Session 209: Immunometabolism and ICI Resistance
Co-Chairs:
Susan M. Kaech, PhD – Salk Institute
Maxim N. Artyomov, PhD– Washington University School of Medicine in St. Louis
3:20–4:50 p.m. EST
(CE Credit Available)

3:20 p.m.

no_symbol.pngMetabolic Regulation of Anti-Tumor NK cells
Susan M. Kaech, PhD – Salk Institute

3:45 p.m.

Metabolic Processes that Affect Anti-Tumor Immune Responses (View On-Demand)
Santosh Vardhana, MD, PhD – Memorial Sloan Kettering Cancer Center

4:10 p.m.

no_symbol.pngTargeting Metabolism to Enhance Cancer Immunotherapy
Jonathan D. Powell, MD, PhD – Johns Hopkins Medicine

4:35 p.m.

no_symbol.png(515_ Metabolic reprogramming of antitumor CD8+ T cell immunity
Alison Jaccard, MS – Université de Lausanne

Session 210: E-Poster Viewing Session

4:50–5:20 p.m. EST

5:20–7 p.m. EST

Break

5–6 p.m. EST

Virtual Exhibit and Poster Hall Hours

Replay Session with Live Q&A: Session 202: Late-Breaking Abstracts

7–8 p.m. EST

Co-Chair:
Sandra Demaria, MD – Weill Cornell Medicine

Replay Session with Live Q&A: Session 203: Rapid Oral Abstracts: Basic Research

7–8 p.m. EST

Co-Chairs:
Kristin Anderson, PhD – Fred Hutchinson Cancer Research Center
Spencer Wei, PhD – Spotlight Therapeutics 

Replay Session with Live Q&A: Session 204: Rapid Oral Abstracts: Clinical

7–8 p.m. EST

Co-Chairs:
Robyn Gartrell, MD, MS – Columbia University
Saman Maleki, PhD – Western University

On-Demand Sessions

Update Session: National Cancer Institute (NCI) (View On-Demand)
Norman E. Sharpless, MD - National Cancer Institute

no_symbol.pngUpdate Session: Food and Drug Administration (FDA)
Raj Puri, MD, PhD – U.S. Food and Drug Administration

no_symbol.pngUpdate Session: FDA Oncology Center of Excellence (FDA OCE)
Marc Theoret, MD – U.S. Food and Drug Administration

Update Session: Cancer Immunotherapy Trials Network (CITN) (View On-Demand)
Martin A. Cheever, MD - Fred Hutchinson Cancer Research Center

no_symbol.pngUpdate Session: SITC Policy Committee
George J. Weiner, MD - University of Iowa, Holden Comprehensive Cancer Center

Update Session: SITC Women in Cancer Immunotherapy Network (WIN) (View On-Demand)
Lisa H. Butterfield, PhD – Parker Institute for Cancer Immunotherapy

no_symbol.pngUpdate Session: International Neoadjuvant Melanoma Consortium (INMC)
Elizabeth M. Burton, MBA – MD Anderson Cancer Center

Friday, Nov. 13, 2020

Annual Meeting

8:00 a.m.–8 p.m. EST*

no_symbol.png
Indicates that the presentation is not available on-demand.

SITC Membership Business Meeting
Chair: Mario Sznol, MD – Yale School of Medicine
8-8:30 a.m.

8 a.m.

SITC Membership Business Meeting

Anniversary Awards Ceremony
Chair: Mario Sznol, MD – Yale School of Medicine
8:30–9 a.m. EST

8:30 a.m.

Introduction
Mario Sznol, MD – Yale School of Medicine

8:32 a.m.

Extraordinary Service to JITC Awards

8:37 a.m.

Collaborator Awards

8:47 a.m.

NCI Collaboration

8:51 a.m.

Closing
Mario Sznol, MD – Yale School of Medicine
Session 300: 35th Anniversary Keynote Address: T cell Therapy of Cancer
Chair:
Mario Sznol, MD – Yale School of Medicine
9–9:50 a.m. EST
(CE Credit Available)

9 a.m.

Introduction
Mario Sznol, MD – Yale School of Medicine

9:05 a.m.

no_symbol.pngT cell Therapy of Cancer
Helen E. Heslop, MD – Baylor College of Medicine

9:45 a.m.

Q&A
Helen E. Heslop, MD – Baylor College of Medicine

9:50–10:05 a.m. EST

Break

Session 301: Hot Topic Symposium: COVID-19 and Cancer
Co-Chairs:
Jedd D. Wolchok, MD, PhD – Memorial Sloan Kettering Cancer Center
Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute, Icahn School of Medicine at Mt. Sinai

10:05 a.m.–12:40 p.m. EST
(CE Credit Available)

10:05 a.m.

no_symbol.pngInfection/Immunology 
Florian Krammer, PhD - Icahn School of Medicine at Mount Sinai

10:30 a.m.

no_symbol.pngInfection in Cancer Patients Specifically
Elizabeth V. Robilotti, MD, MPH – Memorial Sloan Kettering Cancer Center

10:55-11:05 a.m.

Break

11:05 a.m.

Repurposing Cancer Immunotherapies for COVID (View On-Demand)
Paolo Ascierto , MD – Istituto Nazionale Tumori IRCCS Fondazione 'G. Pascale

11:15 a.m.

no_symbol.pngBig Data and Informatics – Viral Sequencing and Epitope Identification
Benjamin Greenbaum, MD – Memorial Sloan Kettering Cancer Center

11:25 a.m.

Big data and Informatics – Viral Sequencing and Epitope Identification (View On-Demand)
Marta Luksza, PhD – Icahn School of Medicine at Mount Sinai

11:35 a.m.

Q&A

11:55 a.m.

Panel Discussion: Immunotherapy and COVID Outcomes (ICIs) and Cancer Care in Pandemic
Jia Luo, MD – Memorial Sloan Kettering Cancer Center
Aljosja Rogiers, MD – Institute of Melanoma

12:15 p.m.

(325) Immunotherapy with B cell activating antibody CPI-006 in patients (pts) with mild to moderate COVID-19 stimulates anti-SARS-CoV-2 antibody response, memory B cells and memory T effector cells (View On-Demand)
Gerard Criner, MD – Temple University

12:25 p.m.

no_symbol.png(475) Incidental finding of colorectal cancer in a COVID-19 patient, followed by deep profiling of SARS-CoV-2-associated immune landscape and tumour microenvironment
Chun Chau Lawrence Cheung, BA, MMedSc - Singapore General Hospital

12:35 p.m.

Closing

12:40–1 p.m. EST

Break

12:30–1:30 p.m. EST

Virtual Exhibit and Poster Hall Hours

Session 302: Late-Breaking Abstract Session
1–1:30 p.m. EST
Chair:
Roberta Zappasodi, PhD – Weill Cornell Medicine
(CE Credit Available)

1 p.m.

(795) A multicenter phase II trial (SWOG S1609, Cohort 51) of Ipilimumab and Nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) (View On-Demand)
Michael Wagner, MD – University of Washington

1:15 p.m.

(812) Urelumab (anti-CD137 agonist) in combination with vaccine and nivolumab treatments is safe and associated with pathologic response as neoadjuvant and adjuvant therapy for resectable pancreatic cancer (View On-Demand)
Lei Zheng, MD, PhD – Johns Hopkins University School of Medicine

Session 303: Presidential Session
Chair:
Mario Sznol, MD – Yale School of Medicine
1:30–2:55 p.m. EST
(CE Credit Available)

1:30 p.m.

Introduction
Mario Sznol, MD – Yale School of Medicine

1:35 p.m.

(528) Sexual dimorphism in myeloid-derived suppressor cells promote GBM progression in females via IL-1b (View On-Demand)
Defne Bayik, PhD - Cleveland Clinic

1:50 p.m.

(36) Molecular events regulating solid tumor cell responses to natural killer cells (View On-Demand)
Michal Sheffer, PhD - Dana-Farber Cancer Institute

2:05 p.m.

Expert Discussant
Jeffrey Miller, MD – University of Minnesota

2:15 p.m.

no_symbol.png(629) Targeting a shared TP53 neoantigen with bispecific T cell retargeting antibody
Emily Hsiue, MD - Oncology

2:30 p.m.

(465) Radiotherapy and CTLA-4 blockade expand anti-tumor T cells differentiation states and cooperate with CD40 agonist to induce tumor rejection (View On-Demand)
Nils Rudqvist, PhD - The University of Texas MD Anderson Cancer Center

2:45 p.m.

Expert Discussant
Robert H. Vonderheide, MD, Dphil – University of Pennsylvania Perelman School of Medicine

2:55–3:10 p.m. EST

Break

Concurrent Session 304: Novel immunotherapies in Myeloid Malignancies
Co-Chairs:
Naval Daver, MD – The University of Texas MD Anderson Cancer Center
Marcela V. Maus, MD, PhD– Massachusetts General Hosptial
3:10–4:40 p.m. EST
(CE Credit Available)

3:10 p.m.

CD47 Macrophage Checkpoint-Based Immunotherapy (Lymphomas, MDS, AML) (View On-Demand)
David Sallman, MD  Moffitt Cancer Center

3:30 p.m.

no_symbol.pngBispecific Antibodies
Marion Subklewe, MD – University of Munich

3:50 p.m.

CAR T for AML (View On-Demand)
Elizabeth Budde, MD, PhD – City of Hope

4:10 p.m.

Emerging and personalized cellular therapy approaches for myeloid diseases (View On-Demand)
Marco L. Davila, MD, PhD – Moffitt Cancer Center

Concurrent Session 305: Reverse Translation for Clinical Trials
Co-Chairs:
Matthew Galsky, MD – Tisch Cancer Institute at Mount Sinai Medical Center
Padmanee Sharma, MD, PhD
 – The University of Texas MD Anderson Cancer Center
3:10–4:40 p.m. EST
(CE Credit Available)

3:10 p.m.

Rational Design of Tumor-Specific Therapeutic and Biomarker Strategies through Reverse Translational Studies (View On-Demand)
Sangeeta Goswami, MD, PhD – MD Anderson Cancer Center

3:30 p.m.

no_symbol.pngClinical Trial Design Considerations to Facilitate Reverse Translation
Thomas Marron, MD, PhD – Icahn School of Medicine at Mount Sinai

3:50 p.m.

no_symbol.pngIdentifying Novel Therapeutics Targets to Overcome Immune Checkpoint Blockade Resistance Through Reverse Translation
Sanjeev Mariathasan, PhD – Genentech
(*No Credit)

4:10 p.m.

no_symbol.png(332) Novel TGF-β signatures in metastatic colorectal cancer patients treated with vactosertib in combination with pembrolizumab
Keun-Wook Lee, MD, PhD – Seoul National University College of Medicine

4:25 p.m.

(352) Updated clinical data from the squamous cell carcinoma of the head and neck (SCCHN) expansion cohort of an ongoing Ph1/1b Study of eganelisib (formerly IPI-549) in combination with nivolumab (View On-Demand)
Ezra Cohen, MD – University of California San Diego

Concurrent Session 306: Engineering Immunity: Biomolecular and Genetic Approaches to Generating Novel Therapeutic Function
Co-Chairs:
Yvonne Chen, PhD – University of California, Los Angeles
Kole T. Roybal, PhD – University of California, San Francisco
3:10–4:40 p.m. EST
(CE Credit Available)

3:10 p.m.

Biomaterials – Basic Biology (View On-Demand)
Jennifer H. Elisseeff, PhD – Johns Hopkins School of Medicine

3:35 p.m.

no_symbol.pngBiomaterials – Immunotherapy
Darrell J. Irvine, PhD – MIT

4 p.m.

no_symbol.pngLymphatic Transport and Anti-Tumor Immunity
Amanda Lund, PhD – NYU Grossman School of Medicine

4:25 p.m.

(587) Tumor-activated Fc-engineered anti-CTLA-4 monoclonal antibody, XTX101, demonstrates tumor-selective PD and efficacy in preclinical models (View On-Demand)
Kurt Jenkins, PhD – Xilio Therapeutics
(*No Credit)

Concurrent Session 307: B Cells
Co-Chairs:
Tullia Bruno, PhD – UPMC Hillman Cancer Center
Wolf Fridman, MD, PhD – Cordeliers Research Centre
3:10–4:40 p.m. EST
(CE Credit Available) 

3:10 p.m.

B cells and Tertiary Lymphoid Structures as biomarkers for prognosis and immunotherapy (View On-Demand)
Wolf H. Fridman, MD, PhD – Cordeliers Research Centre

3:30 p.m.

no_symbol.pngThe Role of B cells and TLS in Immunotherapy Response
Jennifer Wargo, MD – The University of Texas MD Anderson Cancer Center

3:50 p.m.

no_symbol.pngTargeting tertiary lymphoid structure heterogeneity and B cell function in non-small cell lung cancer patients
Tullia C. Bruno, PhD – UPMC Hillman Cancer Center

4:10 p.m.

no_symbol.png(536) Divergent cancer etiologies drive distinct B cell signatures and tertiary lymphoid structures in head and neck cancer
Ayana Ruffin, MS – University of Pittsburgh

4:17 p.m.

(167) B-cell-based vaccination elicit potent immunity against glioblastoma (View On-Demand)
Catalina Lee-Chang, PhD – Northwestern University

4:24 p.m.

Expert Discussant
Brad Nelson, PhD – Deely Research Centre at BC Cancer Agency

4:30 p.m.

Q&A

Session 308: E-Poster Viewing Session

4:40–5:10 p.m. EST

4:30–5:30 p.m. EST

Virtual Exhibit and Poster Hall Hours

5:10–7 p.m. EST

Break

Replay Session with Live Q&A: Session 302: Late-Breaking Abstracts

7–8 p.m. EST

Chair:
Roberta Zappasodi, PhD – Weill Cornell Medicine

On-Demand Sessions

Update Session: National Cancer Institute (NCI) (View On-Demand)
Norman E. Sharpless, MD - National Cancer Institute

no_symbol.pngUpdate Session: Food and Drug Administration (FDA)
Raj Puri, MD, PhD – U.S. Food and Drug Administration

no_symbol.pngUpdate Session: FDA Oncology Center of Excellence (FDA OCE)
Marc Theoret, MD – U.S. Food and Drug Administration

Update Session: Cancer Immunotherapy Trials Network (CITN) (View On-Demand)
Martin A. Cheever, MD - Fred Hutchinson Cancer Research Center

no_symbol.pngUpdate Session: SITC Policy Committee
George J. Weiner, MD - University of Iowa, Holden Comprehensive Cancer Center

Update Session: SITC Women in Cancer Immunotherapy Network (WIN) (View On-Demand)
Lisa H. Butterfield, PhD – Parker Institute for Cancer Immunotherapy

no_symbol.pngUpdate Session: International Neoadjuvant Melanoma Consortium (INMC)
Elizabeth M. Burton, MBA – MD Anderson Cancer Center

Saturday, Nov. 14, 2020

Annual Meeting

8:30 a.m.–4:30 p.m. EST*

no_symbol.png
Indicates that the presentation is not available on-demand.

Anniversary Awards Ceremony
Chair: Mario Sznol, MD – Yale School of Medicine
8:30–9 a.m. EST

8:30 a.m.

Introduction
Mario Sznol, MD – Yale School of Medicine

8:33 a.m.

Team Science Award

Session 400: 35th Anniversary Session: Mechanistic Understandings and Misunderstandings

Co-Chairs:
James P. Allison, PhD – The University of Texas MD Anderson Cancer Center
John Wherry, PhD – University of Pennsylvania
9–10:30 a.m. EST
(CE Credit Available)

9 a.m.

New insights into mechanisms of CTLA-4 and PD-1 blockade in cancer therapy (View On-Demand)
James P. Allison, PhD – The University of Texas MD Anderson Cancer Center

9:15 a.m.

no_symbol.pngEpigenetics of CD8 T Cell Exhaustion
John Wherry, PhD – University of Pennsylvania

9:30 a.m. 

no_symbol.pngRe-assessing the mechanism of checkpoint inhibition
Ira Mellman, PhD – Genentech
(*No Credit)

10:30 a.m.

no_symbol.pngUnderstanding immune responses to cancer using single-cell data
Matthew Spitzer, PhD – University of California San Francisco
(*No Credit)

10:30–10:45 a.m. EST

Break

Session 401: Biomarkers and Big Data
Co-Chairs:
Michael Angelo, MD, PhD – Stanford University
Nir Hacohen, PhD – Broad Institute
10:45 a.m.–12:40 p.m. EST
(CE Credit Available)

10:45 a.m.

Introduction
Nir Hacohen, PhD – Broad Institute

10:55 a.m.

no_symbol.pngSpatial Analysis of Immune Responses in Tumors
Leeat Keren, PhD – Stanford University

11:20 a.m.

Blood-Based Predictors of Tumor Immunity (View On-Demand)
Jane Grogan, PhD – ArsenalBio
(*No Credit)

11:45 a.m.

Capturing heterogeneity and the HLA-presented landscape in melanoma (View On-Demand)
Yardena Samuels, PhD – Weizmann Institute of Science

12:10 p.m.

no_symbol.png(62) Identify immune cell types and biomarkers associated with immune-related adverse events using single cell RNA sequencing
Jiamin Chen, PhD – Stanford University Medical School

12:25 p.m.

no_symbol.png(21) Plasma-based proteomic profiling as a tool for predicting response to immunotherapy in melanoma patients 
Michal Harel, PhD – Oncohost LTD
(*No Credit)

12:30–1:30 p.m. EST Virtual Exhibit and Poster Hall Hours

12:40–1 p.m. EST

Break

Session 402: E-Poster Viewing Session

1–1:30 p.m. EST

Session 403: Poster Symposium
Co-Chairs:
Niroshana Anandasabapathy, MD, PhD – Weill Cornell Medicine
Sangeeta Goswami, MD, PhD – The University of Texas MD Anderson Cancer Center
1:30–2:45 p.m. EST

1:30 p.m.

(545) Tumor-specific cytolitic CD4 T cells mediate protective immunity against human cancer (View On-Demand)
Camilla Jandus, MD, PhD – University of Geneva

 1:40 p.m.

no_symbol.png(206) An immune-competent tumor organoid platform to test novel immune checkpoint combinations targeting the receptor CD47 in triple negative breast cancer
Elizabeth R. Stirling, MS – Wake Forest University

 1:50 p.m.

(549) Characterizing Double Positive T cells in the Tumor Microenvironment: a tale of promiscuous cell fates (View On-Demand)
Sara Schad, BS – Memorial Sloan Kettering Cancer Center

 2 p.m.

(152) Adoptive T cell therapy targeting somatic p53 mutations (View On-Demand)
Peter Kim, PhD – National Institute of Health

 2:10 p.m.

(744) Single cell profiling of acute myeloid leukemia (AML) and its microenvironment reveals a CD8 continuum and adaptable T cell plasticity in response to PD-1 blockade-based therapy (View On-Demand)
Hussein Abbas, MD, PhD – The University of Texas MD Anderson Cancer Center

2:20 p.m.

(248) Immunotherapy persister cells uncovered by dynamic single-cell RNA-sequencing (View On-Demand)
Kartik Sehgal, MD – Dana Farber Cancer Institute

2:30 p.m.

Q&A

2:45–3 p.m. EST

Break

Session 404: Next Generation Immunotherapy Combinations: Navigating FDA, Clinical Trial Design, Diagnostics and Novel Biomarkers
Co-Chairs:
Emily Hopewell, PhD – Indiana University
Ke Liu, MD, PhD – Food and Drug Administration (FDA)
Jason Luke, MD – UPMC Hillman Cancer Center
Marc Theoret, MD – Food and Drug Administration (FDA), CDER
3–4:30 p.m. EST
(CE Credit Available)

3 p.m.

Welcome
Jason Luke, MD – UPMC Hillman Cancer Center

3:05 p.m.

Navigating the Road to Developing and Pursuing Novel Cellular and Non-Cellular Combination Immunotherapy Clinical Trials: FDA Overview (View On-Demand)
Adnan A. Jaigirdar, MD, FACS - Food and Drug Administration

3:20 p.m.

FDA Perspective on Areas of Research Needed in Advancing Neo-Adjuvant Immunotherapy Toward Clinical Practice (View On-Demand)
Nicole Drezner, MD – Food and Drug Administration

3:35 p.m.

Difficulties and opportunities in developing cellular therapy and cancer therapeutics clinical trials: science and logistics for investigators (View On-Demand)
Cassian Yee, MD – The University of Texas MD Anderson Cancer Center

3:50 p.m.

Improving patient selection in cellular therapy studies and neoadjuvant trials (View On-Demand)
Rodabe N. Amaria, MD – The University of Texas MD Anderson Cancer Center

4:05 p.m.

Panel Discussion

Closing Remarks
Chair: Mario Sznol, MD – Yale School of Medicine
4:30 p.m. EST

4:30 p.m.

SITC 2020 Closing Remarks
Mario Sznol, MD – Yale School of Medicine

On-Demand Sessions

Update Session: National Cancer Institute (NCI) (View On-Demand)
Norman E. Sharpless, MD - National Cancer Institute

no_symbol.pngUpdate Session: Food and Drug Administration (FDA)
Raj Puri, MD, PhD – U.S. Food and Drug Administration

no_symbol.pngUpdate Session: FDA Oncology Center of Excellence (FDA OCE)
Marc Theoret, MD – U.S. Food and Drug Administration

Update Session: Cancer Immunotherapy Trials Network (CITN) (View On-Demand)
Martin A. Cheever, MD - Fred Hutchinson Cancer Research Center

no_symbol.pngUpdate Session: SITC Policy Committee
George J. Weiner, MD - University of Iowa, Holden Comprehensive Cancer Center

Update Session: SITC Women in Cancer Immunotherapy Network (WIN) (View On-Demand)
Lisa H. Butterfield, PhD – Parker Institute for Cancer Immunotherapy

no_symbol.pngUpdate Session: International Neoadjuvant Melanoma Consortium (INMC)
Elizabeth M. Burton, MBA – MD Anderson Cancer Center

Schedule At-a-Glance

Monday, Nov. 9
Pre-Conference Programs
(Additional Fees Required)

Immunotherapy Resistance and Failure

Workshop on Engineering Immune Cells for Cancer Therapy

Tuesday, Nov. 10
Pre-Conference Programs
(Additional Fees Required)
Primer on Tumor Immunology and Cancer Immunotherapy™
Grant Writing Workshop
Wednesday, Nov. 11
Annual Meeting

35th Anniversary Annual Meeting

Thursday, Nov. 12
Annual Meeting

35th Anniversary Annual Meeting

Friday, Nov. 13
Annual Meeting


35th Anniversary Annual Meeting

Saturday, Nov. 14
Annual Meeting

35th Anniversary Annual Meeting